1. VAN WYK, J. et al. Variables associated with neuropsychiatric symptoms in PLWH receiving dolutegravir based therapy in phase III clinical trials. Pôster TUPDB0102. In: 22nd International AIDS Conference, 2018. Amsterdam. Disponível em: <https://programme.aids2018.org//PAGMaterial/eposters/12021.pdf>. Acesso em: 25 jul. 2018.
2. NWOSU, EC. et al. Antiretroviral therapy (ART) interruption is associated with reduced cortical structures compared to uninterrupted ART at age 5 years in HIV-infected children on early ART.Pôster TUPDB0103. In: 22nd International AIDS Conference, 2018. Amsterdam. Disponível em: <https://programme.aids2018.org//PAGMaterial/eposters/6121.pdf>. Acesso em: 25 jul. 2018.
3. NWOSU, EC. et al. Antiretroviral therapy (ART) interruption is associated with reduced cortical structures compared to uninterrupted ART at age 5 years in HIV-infected children on early ART. Slides. In: 22nd International AIDS Conference, 2018. Amsterdam. Disponívelem: <https://programme.aids2018.org/PAGMaterial/PPT/2138_3775/Final-Oral-presentation-Emmanuel-Farai-AIDS-2018.pptx>. Acesso em: 25 jul. 2018.
4. CUZIN, L. et al. Integrase inhibitors and neuropsychiatric adverse events in a large prospective cohort. Pôster TUPDB0107.In: 22nd International AIDS Conference, 2018. Amsterdam.Disponível em: <https://programme.aids2018.org//PAGMaterial/eposters/5059.pdf>. Acesso em: 25 jul. 2018.